BMO on BioNTech (BNTX): 'Cancer Vaccine Updates at AACR Incrementally Positive in Our View'
Tweet Send to a Friend
BMO Capital analyst Etzer Darout reiterated an Outperform rating and $123.00 price target on BioNTech (NASDAQ: BNTX).The analyst comments "Vaccines ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
